Journal of Clinical Oncology, Vol 10, 541-548, Copyright © 1992 by American Society of Clinical Oncology

ARTICLES

FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer

D Kelsen, OT Atiq, L Saltz, D Niedzwiecki, D Ginn, D Chapman, R Heelan, C Lightdale, V Vinciguerra and M Brennan
Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.

PURPOSE: The chemotherapy regimens of high-dose methotrexate, high-dose fluorouracil (FU), Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH), and leucovorin (FAMTX) and etoposide, Adriamycin, and cisplatin (EAP) have both been reported in nonrandom assignment trials to have high overall response rates and substantial complete response rates in patients with gastric cancer, as well as major toxicities of myelosuppression. Here we report a prospective, stratified, random- assignment comparison of the two combinations in previously untreated patients with advanced gastric cancer. PATIENTS AND METHODS: Sixty patients were entered onto the trial, 30 receiving EAP and 30 FAMTX. All patients had measurable or assessable tumor masses. Patient entry was stopped at the point when significant toxicity differences were seen at interim analysis. RESULTS: Response rates were similar between the two arms (FAMTX, 33% [95% confidence interval (CI), 16% to 50%]; EAP, 20% [95% Cl, 6% to 34%]). Three FAMTX and no EAP patients had complete remissions. The median survival for the two arms were similar (EAP, 6.1 months; FAMTX, 7.3 months). At 1 year, 7% of EAP and 17% of FAMTX patients were alive. EAP caused significantly more myelosuppression (leukopenia, P = .002; anemia, P = .03; thrombocytopenia, P = .0001) than did FAMTX. EAP also resulted in significantly longer hospitalizations per study month (8 v 5 days). Four EAP patients died of lethal toxicity, whereas no FAMTX patients died of treatment-related causes (P = .04). CONCLUSIONS: FAMTX is at least as active as EAP and is significantly less toxic. Although both regimens remain investigational, the toxicities of FAMTX are more manageable. Further studies involving FAMTX in both the adjuvant and advanced disease setting are underway.

This article has been cited by other articles:

				Y. Sakurai, I. Yoshida, S. Kamoshida, K. Inaba, J. Isogaki, Y. Komori, I. Uyama, and Y. Tsutsumi Effects of Combined Administration of DPD-Inhibitory Oral Fluoropyrimidine, S-1, Plus Paclitaxel on Gene Expressions of Fluoropyrimidine Metabolism-Related Enzymes in Human Gastric Xenografts Ann. Surg. Oncol., August 1, 2008; 15(8): 2301 - 2309. [Abstract] [Full Text] [PDF]

				N. Boku, A. Ohtsu, F. Nagashima, K. Shirao, and W. Koizumi Relationship between Expression of Vascular Endothelial Growth Factor in Tumor Tissue from Gastric Cancers and Chemotherapy Effects: Comparison between S-1 alone and the Combination of S-1 plus CDDP Jpn. J. Clin. Oncol., August 2, 2007; (2007) hym057v1. [Abstract] [Full Text] [PDF]

				M. P. Lutz, H. Wilke, D.J. T. Wagener, U. Vanhoefer, K. Jeziorski, S. Hegewisch-Becker, L. Balleisen, E. Joossens, R. L. Jansen, M. Debois, et al. Weekly Infusional High-Dose Fluorouracil (HD-FU), HD-FU Plus Folinic Acid (HD-FU/FA), or HD-FU/FA Plus Biweekly Cisplatin in Advanced Gastric Cancer: Randomized Phase II Trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie J. Clin. Oncol., June 20, 2007; 25(18): 2580 - 2585. [Abstract] [Full Text] [PDF]

				D. W. Gee and D. W. Rattner Management of Gastroesophageal Tumors Oncologist, February 1, 2007; 12(2): 175 - 185. [Abstract] [Full Text] [PDF]

				W Ichikawa and Y Sasaki Correlation between tumor response to first-line chemotherapy and prognosis in advanced gastric cancer patients Ann. Onc., November 1, 2006; 17(11): 1665 - 1672. [Abstract] [Full Text] [PDF]

				L. Lim, M. Michael, G. B. Mann, and T. Leong Adjuvant Therapy in Gastric Cancer J. Clin. Oncol., September 1, 2005; 23(25): 6220 - 6232. [Abstract] [Full Text] [PDF]

				I. S. Woo, D. H. Moon, B. Y. Shim, M. A. Lee, J. H. Byun, K. W. Kim, J.-H. Kang, M. G. Choi, I.-S. Chung, Y. S. Hong, et al. A Phase II Study of Epirubicin, Cisplatin and Uracil-Tegafur for Advanced Gastric Carcinoma Jpn. J. Clin. Oncol., January 1, 2005; 35(1): 13 - 17. [Abstract] [Full Text] [PDF]

				C. Pozzo, C. Barone, J. Szanto, E. Padi, C. Peschel, J. Bukki, V. Gorbunova, V. Valvere, J. Zaluski, M. Biakhov, et al. Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study Ann. Onc., December 1, 2004; 15(12): 1773 - 1781. [Abstract] [Full Text] [PDF]

				O. Bouche, J. L. Raoul, F. Bonnetain, M. Giovannini, P. L. Etienne, G. Lledo, D. Arsene, J. F. Paitel, V. Guerin-Meyer, E. Mitry, et al. Randomized Multicenter Phase II Trial of a Biweekly Regimen of Fluorouracil and Leucovorin (LV5FU2), LV5FU2 Plus Cisplatin, or LV5FU2 Plus Irinotecan in Patients With Previously Untreated Metastatic Gastric Cancer: A Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803 J. Clin. Oncol., November 1, 2004; 22(21): 4319 - 4328. [Abstract] [Full Text] [PDF]

				S. S. Wohrer, M. Raderer, and M. Hejna Palliative chemotherapy for advanced gastric cancer Ann. Onc., November 1, 2004; 15(11): 1585 - 1595. [Abstract] [Full Text] [PDF]

				J. Souglakos, K. Syrigos, A. Potamianou, A. Polyzos, I. Boukovinas, N. Androulakis, Ch. Kouroussis, N. Vardakis, Ch. Christophilakis, A. Kotsakis, et al. Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: a multicentre phase II trial Ann. Onc., August 1, 2004; 15(8): 1204 - 1209. [Abstract] [Full Text] [PDF]

				T. D. Shanafelt, C. Loprinzi, R. Marks, P. Novotny, and J. Sloan Are Chemotherapy Response Rates Related to Treatment-Induced Survival Prolongations in Patients With Advanced Cancer? J. Clin. Oncol., May 15, 2004; 22(10): 1966 - 1974. [Abstract] [Full Text] [PDF]

				L. Assersohn, G. Brown, D. Cunningham, C. Ward, J. Oates, J. S. Waters, M. E. Hill, and A. R. Norman Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma Ann. Onc., January 1, 2004; 15(1): 64 - 69. [Abstract] [Full Text] [PDF]

				A. D. Roth Chemotherapy in gastric cancer: a never ending saga Ann. Onc., February 1, 2003; 14(2): 175 - 177. [Full Text] [PDF]

				A. Ohtsu, Y. Shimada, K. Shirao, N. Boku, I. Hyodo, H. Saito, N. Yamamichi, Y. Miyata, N. Ikeda, S. Yamamoto, et al. Randomized Phase III Trial of Fluorouracil Alone Versus Fluorouracil Plus Cisplatin Versus Uracil and Tegafur Plus Mitomycin in Patients With Unresectable, Advanced Gastric Cancer: The Japan Clinical Oncology Group Study (JCOG9205) J. Clin. Oncol., January 1, 2003; 21(1): 54 - 59. [Abstract] [Full Text] [PDF]

				C. Louvet, T. Andre, J.M. Tigaud, E. Gamelin, J.Y. Douillard, R. Brunet, E. Francois, J.H. Jacob, D. Levoir, A. Taamma, et al. Phase II Study of Oxaliplatin, Fluorouracil, and Folinic Acid in Locally Advanced or Metastatic Gastric Cancer Patients J. Clin. Oncol., December 1, 2002; 20(23): 4543 - 4548. [Abstract] [Full Text] [PDF]

				P. Ross, M. Nicolson, D. Cunningham, J. Valle, M. Seymour, P. Harper, T. Price, H. Anderson, T. Iveson, T. Hickish, et al. Prospective Randomized Trial Comparing Mitomycin, Cisplatin, and Protracted Venous-Infusion Fluorouracil (PVI 5-FU) With Epirubicin, Cisplatin, and PVI 5-FU in Advanced Esophagogastric Cancer J. Clin. Oncol., April 15, 2002; 20(8): 1996 - 2004. [Abstract] [Full Text] [PDF]

				E. Bajetta, R. Buzzoni, L. Mariani, E. Beretta, F. Bozzetti, G. Bordogna, E. Aitini, S. Fava, G. Schieppati, G. Pinotti, et al. Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group Ann. Onc., February 20, 2002; 13(2): 299 - 307. [Abstract] [Full Text] [PDF]

				N. Boku, A. Ohtsu, F. Nagashima, M. Muto, T. Shinkai, and S. Yoshida Retrospective Study of Hyponatremia in Gastric Cancer Patients Treated with a Combination Chemotherapy of 5-Fluorouracil and Cisplatin: a Possible Warning Sign of Severe Hematological Toxicities? Jpn. J. Clin. Oncol., August 1, 2001; 31(8): 382 - 387. [Abstract] [Full Text] [PDF]

				N. C. Tebbutt, A. Norman, M. Hill, D. Cunningham, and J. A. Ajani Standard Chemotherapy for Gastric Carcinoma: Is It a Myth? J. Clin. Oncol., May 15, 2001; 19(10): 2765 - 2767. [Full Text] [PDF]

				M. H. Kulke The Treatment of Advanced Gastric Cancer: In Search of the Right Combination J. Clin. Oncol., July 14, 2000; 18(14): 2645 - 2647. [Full Text] [PDF]

				U. Vanhoefer, P. Rougier, H. Wilke, M. P. Ducreux, A. J. Lacave, E. Van Cutsem, M. Planker, J. G. D. Santos, P. Piedbois, B. Paillot, et al. Final Results of a Randomized Phase III Trial of Sequential High-Dose Methotrexate, Fluorouracil, and Doxorubicin Versus Etoposide, Leucovorin, and Fluorouracil Versus Infusional Fluorouracil and Cisplatin in Advanced Gastric Cancer: A Trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group J. Clin. Oncol., July 14, 2000; 18(14): 2648 - 2657. [Abstract] [Full Text] [PDF]

				S. Wadler, S. Damle, H. Haynes, R. Kaleya, R. Schechner, R. Berkenblit, R. D. Ladner, and A. Murgo Phase II/Pharmacodynamic Trial of Dose-Intensive, Weekly Parenteral Hydroxyurea and Fluorouracil Administered With Interferon Alfa-2a in Patients With Refractory Malignancies of the Gastrointestinal Tract J. Clin. Oncol., June 1, 1999; 17(6): 1771 - 1771. [Abstract] [Full Text] [PDF]

				N. Boku, A. Ohtsu, Y. Shimada, K. Shirao, S. Seki, H. Saito, Y. Sakata, and I. Hyodo Phase II Study of a Combination of Irinotecan and Cisplatin Against Metastatic Gastric Cancer J. Clin. Oncol., January 1, 1999; 17(1): 319 - 319. [Abstract] [Full Text] [PDF]

				A. Bamias and N. Pavlidis Systemic Chemotherapy in Gastric Cancer: Where Do We Stand Today? Oncologist, June 1, 1998; 3(3): 171 - 177. [Abstract] [Full Text]

				I. Songun and C. J.H. van de Velde Can Surgical Treatment Results in Gastric Cancer Be Improved? Oncologist, February 1, 1996; 1(1): 36 - 40. [Abstract] [Full Text] [PDF]

				C. S. Fuchs and R. J. Mayer Gastric Carcinoma N. Engl. J. Med., July 6, 1995; 333(1): 32 - 41. [Full Text] [PDF]